Sagent Pharmaceuticals, Inc. 4
4 · Sagent Pharmaceuticals, Inc. · Filed Aug 31, 2016
Insider Transaction Report
Form 4
OBERMAN ALLAN
DirectorChief Executive Officer
Transactions
- Disposition to Issuer
Common Stock
2016-08-29$21.75/sh−9,459$205,733→ 92,527 total - Disposition to Issuer
Common Stock
2016-08-29$21.75/sh−92,527$2,012,462→ 0 total - Disposition to Issuer
Stock Option to Buy
2016-08-29$7.14/sh−108,696$776,089→ 0 totalExercise: $14.61Exp: 2026-02-22→ Common Stock (108,696 underlying)
Footnotes (3)
- [F1]Pursuant to the Agreement and Plan of Merger by and among Nichi-Iko Pharmaceutical Co. Ltd., Shepard Vision, Inc. and Sagent Pharmaceuticals, Inc. (the "Merger Agreement"), these shares were canceled and converted into the right to receive $21.75 per share in cash, without interest, less any applicable withholding taxes (the "Merger Consideration").
- [F2]Pursuant to the Merger Agreement, these restricted shares were canceled and converted into the right to receive the Merger Consideration.
- [F3]Represents the disposition of options, which provided for vesting in four equal installments beginning February 22, 2017. The options were cancelled pursuant to the Merger Agreement in exchange for a cash payment of $7.14 per share subject to the option. This per share price represents the difference between the applicable exercise price of the option and the Merger Consideration.